
Stephanie K Dougan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1277245/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tissue eosinophils express the ILâ€33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 656-660.	5.7	8
2	Dangerous dynamic duo: Lactic acid and PD-1 blockade. Cancer Cell, 2022, 40, 127-130.	16.8	10
3	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	13.2	90
4	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. Immunotherapy Advances, 2021, 1, Itab011.	3.0	13
5	Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell, 2021, 184, 1575-1588.	28.9	111
6	EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	13.2	118
7	cIAP1/2 antagonism eliminates MHC class l–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes. Science Translational Medicine, 2021, 13, .	12.4	25
8	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discovery, 2021, 11, 2564-2581.	9.4	58
9	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	3.0	103
10	Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biology, 2021, 11, 210245.	3.6	15
11	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell, 2020, 182, 655-671.e22.	28.9	259
12	Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology, 2020, 10, 190235.	3.6	11
13	Programmable bacteria as cancer therapy. Nature Medicine, 2019, 25, 1030-1031.	30.7	29
14	SMAC mimetics throw a molecular switch to control T _H 17 responses. Science Signaling, 2019, 12, .	3.6	1
15	Transnuclear mice reveal Peyer's patch iNKT cells that regulate Bâ€cell class switching to IgG1. EMBO Journal, 2019, 38, e101260.	7.8	3
16	GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity, 2019, 50, 796-811.	14.3	274
17	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology, 2019, 156, 2056-2072.	1.3	300
18	Cancer Immunotherapy: Beyond Checkpoint Blockade. Annual Review of Cancer Biology, 2019, 3, 55-75.	4.5	102

STEPHANIE K DOUGAN

#	Article	IF	CITATIONS
19	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs. Cancer Immunology Research, 2018, 6, 389-401.	3.4	68
20	Anti–CTLA-4 therapy requires an Fc domain for efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3912-3917.	7.1	121
21	IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunology Research, 2018, 6, 25-35.	3.4	27
22	Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses. Cancer Immunology Research, 2018, 6, 1524-1536.	3.4	17
23	Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. Journal of Experimental Medicine, 2018, 215, 2617-2635.	8.5	20
24	Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy, 2018, 10, 787-796.	2.0	51
25	Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Frontiers in Immunology, 2018, 9, 2030.	4.8	77
26	Monoclonal Invariant NKT (iNKT) Cell Mice Reveal a Role for Both Tissue of Origin and the TCR in Development of iNKT Functional Subsets. Journal of Immunology, 2017, 199, 159-171.	0.8	30
27	CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10449-10454.	7.1	26
28	PD-L1 is an activation-independent marker of brown adipocytes. Nature Communications, 2017, 8, 647.	12.8	97
29	Localized CD47 blockade enhances immunotherapy for murine melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10184-10189.	7.1	103
30	Generation of Ca2+-independent sortase A mutants with enhanced activity for protein and cell surface labeling. PLoS ONE, 2017, 12, e0189068.	2.5	34
31	Longitudinal multiparameter assay of lymphocyte interactions from onset by microfluidic cell pairing and culture. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3599-608.	7.1	78
32	Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature Biotechnology, 2015, 33, 538-542.	17.5	945
33	Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut, 2015, 64, 1889-1897.	12.1	106
34	Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. Journal of Experimental Medicine, 2005, 202, 529-539.	8.5	142